Objectives: The aim of this study was to test choline-phosphate cytidylyltransferase-alpha (CCT-alpha) protein as a biomarker for neoadjuvant cisplatin chemotherapy response in a bladder tumor setting. Materials and methods: A total of 238 patients with T2-T4 bladder cancer enrolled into two prior randomized trials comparing neoadjuvant cisplatin-based chemotherapy (NAC) plus cystectomy with cystectomy only (no-NAC) were used as discovery and validation cohorts. Protein expression was determined with immunohistochemistry and assessed with Histo (H)-scoring. Results: In the discovery cohort, comprising 61 patients, the survival ratio after NAC treatment for CCT-alpha-negative patients was significantly increased (p = 0.001) while there was n...
Patients with muscle-invasive urothelial carcinoma achieving pathological complete response (pCR) up...
OBJECTIVES: To determine the value of the loss of expression of E-cadherin and cadherin associated m...
Introduction: The glycoprotein P-170, causing drug efflux from the cells, may represent at least one...
Objectives: The aim of this study was to test choline-phosphate cytidylyltransferase-alpha (CCT-alph...
Background: Response to neoadjuvant cisplatin treatment in bladder cancer has been linked to express...
BACKGROUND:The 5-year cancer specific survival (CSS) for patients with muscle invasive urothelial ca...
BACKGROUND: The 5-year cancer specific survival (CSS) for patients with muscle invasive urothelial c...
Bladder cancer is a potentially curable malignancy; however in regards to the state of current thera...
Background: For muscle-invasive bladder cancer (MIBC), no tissue biomarkers are available for clinic...
PURPOSE: Resistance to chemotherapy is a major obstacle to overcome in the conservative treatment of...
One of the main genotoxic drugs used in bladder cancer chemotherapy is cisplatin. While it is applie...
Objectives : To evaluate the clinical benefit of neoadjuvant chemotherapy with gemcitabine and cispl...
Urothelial carcinoma of the bladder (UCB) and upper tracts (UTUC) is often regarded as one entity an...
For 40 years cisplatin-based chemotherapy has been administered to patients with muscle-invasive bla...
PURPOSE: After cisplatin-based neoadjuvant chemotherapy (NAC) 60% of patients with muscle-invasive b...
Patients with muscle-invasive urothelial carcinoma achieving pathological complete response (pCR) up...
OBJECTIVES: To determine the value of the loss of expression of E-cadherin and cadherin associated m...
Introduction: The glycoprotein P-170, causing drug efflux from the cells, may represent at least one...
Objectives: The aim of this study was to test choline-phosphate cytidylyltransferase-alpha (CCT-alph...
Background: Response to neoadjuvant cisplatin treatment in bladder cancer has been linked to express...
BACKGROUND:The 5-year cancer specific survival (CSS) for patients with muscle invasive urothelial ca...
BACKGROUND: The 5-year cancer specific survival (CSS) for patients with muscle invasive urothelial c...
Bladder cancer is a potentially curable malignancy; however in regards to the state of current thera...
Background: For muscle-invasive bladder cancer (MIBC), no tissue biomarkers are available for clinic...
PURPOSE: Resistance to chemotherapy is a major obstacle to overcome in the conservative treatment of...
One of the main genotoxic drugs used in bladder cancer chemotherapy is cisplatin. While it is applie...
Objectives : To evaluate the clinical benefit of neoadjuvant chemotherapy with gemcitabine and cispl...
Urothelial carcinoma of the bladder (UCB) and upper tracts (UTUC) is often regarded as one entity an...
For 40 years cisplatin-based chemotherapy has been administered to patients with muscle-invasive bla...
PURPOSE: After cisplatin-based neoadjuvant chemotherapy (NAC) 60% of patients with muscle-invasive b...
Patients with muscle-invasive urothelial carcinoma achieving pathological complete response (pCR) up...
OBJECTIVES: To determine the value of the loss of expression of E-cadherin and cadherin associated m...
Introduction: The glycoprotein P-170, causing drug efflux from the cells, may represent at least one...